Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Pharmazie ; 75(11): 590-594, 2020 11 01.
Article in English | MEDLINE | ID: mdl-33239135

ABSTRACT

Objective: Several studies have suggested an involvement of the immune system in the occurrence and development of chronic obstructive pulmonary disease (COPD), but the mechanism is still unclear. The aim of this study was to explore the mechanism of ginsenoside in inhibiting inflammation by regulating FOXP3 in COPD. Methods: Eighty COPD patients were selected and 35 healthy people were enrolled in the study to determine clinical efficacy, observation index, and SGRQ scores. Percentage of Treg and Th17 cells were detected by flow cytometry; HE staining was used to detect the effect of ginsenoside therapy on pathological changes of COPD in mice. Additionally, we transfected FOXP3 inhibitor; RT-PCR and western blot were used to detect the inflammation related genes and proteins. Results: The basic information of the patients were comparable. The clinical outcome in the treatment group was better than that in the control group, which indicated that ginsenoside has a certain therapeutic effect on COPD patients. The lung function and 6MWT distance results indicated that ginsenoside could stabilize the clinical symptoms of COPD patients and improve their quality of life. Flow cytometry results showed that ginsenoside can increase Treg expression while reducing Th17 cell expression. RT-PCR and western blot results showed that the expression of TNF-α and IL-17 in the model group was significantly increased after treatment, obviously caused by an increased expression of FOXP3. Conclusion: Ginsenoside can inhibit inflammation in COPD by up-regulating FOXP3.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Ginsenosides/pharmacology , Inflammation/drug therapy , Pulmonary Disease, Chronic Obstructive/drug therapy , Animals , Anti-Inflammatory Agents/administration & dosage , Case-Control Studies , Female , Forkhead Transcription Factors/genetics , Ginsenosides/administration & dosage , Humans , Inflammation/physiopathology , Male , Mice , Mice, Inbred C57BL , Pulmonary Disease, Chronic Obstructive/physiopathology , Quality of Life , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology
2.
Zhong Xi Yi Jie He Xue Bao ; 3(5): 363-5, 2005 Sep.
Article in Chinese | MEDLINE | ID: mdl-16159569

ABSTRACT

OBJECTIVE: To investigate the information acquired through the four diagnostic methods of traditional Chinese medicine in patients with bronchial asthma, and to classify the syndrome types. METHODS: Four hundred and thirty patients with bronchial asthma were randomly investigated. The information acquired through the four diagnostic methods was recorded and the database was established by Amos software, and then the data were analyzed by confirmatory factor analysis (CFA). RESULTS: After analyzing the data with 4 factors, 5 factors and 6 factors, we found that the results of CFA with 6 factors were in accordance with clinical practical experience. CONCLUSION: According to the results of CFA with 6 factors and with the standard regression coefficient 0.4 as primary and secondary critical points, the syndromes in patients with bronchial asthma can be classified into 5 types, which are syndromes of cold fluid retained in lung, phlegm-heat obstructing lung, wind-phlegm blocking lung, qi deficiency of lung and kidney and qi deficiency of spleen.


Subject(s)
Asthma/diagnosis , Diagnosis, Differential , Medicine, Chinese Traditional , Adult , Asthma/classification , Factor Analysis, Statistical , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...